AMZN   3,016.39 (+4.36%)
CGC   16.99 (+3.28%)
BABA   237.82 (+6.36%)
GE   6.99 (+2.49%)
TSLA   1,324.69 (+9.60%)
AMD   53.23 (+1.70%)
T   30.47 (+1.30%)
ACB   12.38 (+0.90%)
F   6.17 (+1.98%)
GILD   76.84 (+0.64%)
DIS   113.63 (+1.29%)
BAC   23.69 (+1.72%)
BA   187.26 (+3.57%)
AMZN   3,016.39 (+4.36%)
CGC   16.99 (+3.28%)
BABA   237.82 (+6.36%)
GE   6.99 (+2.49%)
TSLA   1,324.69 (+9.60%)
AMD   53.23 (+1.70%)
T   30.47 (+1.30%)
ACB   12.38 (+0.90%)
F   6.17 (+1.98%)
GILD   76.84 (+0.64%)
DIS   113.63 (+1.29%)
BAC   23.69 (+1.72%)
BA   187.26 (+3.57%)
AMZN   3,016.39 (+4.36%)
CGC   16.99 (+3.28%)
BABA   237.82 (+6.36%)
GE   6.99 (+2.49%)
TSLA   1,324.69 (+9.60%)
AMD   53.23 (+1.70%)
T   30.47 (+1.30%)
ACB   12.38 (+0.90%)
F   6.17 (+1.98%)
GILD   76.84 (+0.64%)
DIS   113.63 (+1.29%)
BAC   23.69 (+1.72%)
BA   187.26 (+3.57%)
AMZN   3,016.39 (+4.36%)
CGC   16.99 (+3.28%)
BABA   237.82 (+6.36%)
GE   6.99 (+2.49%)
TSLA   1,324.69 (+9.60%)
AMD   53.23 (+1.70%)
T   30.47 (+1.30%)
ACB   12.38 (+0.90%)
F   6.17 (+1.98%)
GILD   76.84 (+0.64%)
DIS   113.63 (+1.29%)
BAC   23.69 (+1.72%)
BA   187.26 (+3.57%)
Log in

OTCMKTS:IPHYFInnate Pharma Price Target & Analyst Ratings

$6.06
0.00 (0.00 %)
(As of 07/6/2020 08:38 AM ET)
Add
Compare
Today's Range
$6.06
Now: $6.06
$6.06
50-Day Range
$6.06
MA: $6.54
$7.07
52-Week Range
$3.70
Now: $6.06
$8.12
VolumeN/A
Average Volume181 shs
Market Capitalization$475.95 million
P/E RatioN/A
Dividend YieldN/A
Beta0.55

Analyst Ratings

Innate Pharma (OTCMKTS:IPHYF) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Innate Pharma in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.002.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$11.00$11.00$11.00
Price Target Upside: N/A55.59% upside56.70% upside56.70% upside

Innate Pharma (OTCMKTS:IPHYF) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Innate Pharma (OTCMKTS:IPHYF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/13/2020Kepler Capital MarketsReiterated RatingHold
6/24/2019HC WainwrightReiterated RatingBuy$11.00
6/14/2018SVB LeerinkReiterated RatingOutperform
(Data available from 7/6/2018 forward)
This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.